SCHEMBL7196183

SCHEMBL7196183

CCOC(=O)c1cc2cc(OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)c(OC)cc2n1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 1/20 0.43
SRD5A2 P31213 1/20 0.43
NOD2 Q9HC29 1/20 0.42
NOD1 Q9Y239 1/20 0.42
TDP1 Q9NUW8 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
ABCB1 P08183 2/20 0.40
F10 P00742 3/20 0.39
MAPT P10636 4/20 0.38
ALDH1A1 P00352 3/20 0.38
POLB P06746 3/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 2/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 1/20 0.37
ATM Q13315 1/20 0.37
PTGER1 P34995 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5701947 0.88 SRD5A1 (0.53) SRD5A1SRD5A2ABCB1PTGER1PPARG
SCHEMBL7194615 0.81 SRD5A1 (0.56) SRD5A1SRD5A2PTGER1PPARG
SCHEMBL7200219 0.75 SRD5A1 (0.53) SRD5A1SRD5A2SMN1; SMN2LMNAGAA
SCHEMBL18247599 0.75 GPR35 (0.46) SRD5A1SRD5A2NOD2NOD1TDP1
SCHEMBL7086760 0.72 ABCB11 (0.53) NOD2NOD1TDP1SMN1; SMN2LMNA
SCHEMBL4214845 0.72 CCR9 (0.59)
SCHEMBL3578136 0.72 PPARG (0.54) NOD2NOD1F10MAPTPPARG
SCHEMBL31412992 0.72 SRD5A2 (0.78) SRD5A1SRD5A2SMN1; SMN2HPGD
SCHEMBL6308312 0.72 CCR9 (0.55) SRD5A1SRD5A2PPARG
SCHEMBL7083180 0.71 ABCB11 (0.52) NOD2NOD1TDP1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596753-B2 Effective amount of at least one compound of the indolecarboxylic family, this compound or these compositions being intended to treat disorders associated with overactivity of 5 alpha -reductase. These compositions treat androgen SOCIETE L'OREAL S.A. (FR) 2003-07-22 US disclosed
US-20030050325-A1 Novel compounds of the indolecarboxylic family and use thereof BERNARD BRUNO (FR) 2003-03-13 US disclosed
US-6448285-B1 DISORDERS ASSOCIATED WITH OVERACTIVITY OF 5 ALPHA REDUCTASE; ANDROGEN DEPENDENT DISORDERS SUCH AS SEBORRHOEA, ACNE, HIRSUTISM AND/OR ANDROGENIC ALOPECIA SOCIETE L'OREAL S.A. (FR) 2002-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050325-A1 Novel compounds of the indolecarboxylic family and use thereof CYP17A1, SRD5A1, SRD5A2 SRD5A1 2/4885SRD5A2 3/4885NOD2 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.